



ISPOR 4TH LATIN AMERICA CONFERENCE

NEW! EXTENDED PROGRAM!
~100% increase in abstract submissions!

12-14 SEPTEMBER 2013 • HILTON BUENOS AIRES • BUENOS AIRES, ARGENTINA

Challenges for Health Care Systems in Latin America: Changing Models of HTA, Priority Setting, and Health Rights



PROGRAM

ORGANIZED BY: International Society for Pharmacoeconomics and Outcomes Research (ISPOR) and the ISPOR Latin America Consortium, in coordination with the ISPOR Argentina Regional Chapter

CONFERENCE SUPPORTING INSTITUTIONS (as of May 2013):

- Institute for Clinical Effectiveness and Health Policy (IECS), Argentina
- General Coordination for HTA – Department of Science and Technology (DECIT-CGATS), Ministry of Health, Brazil
- National Commission for the Incorporation of Medical Technologies (CONITEC), Brazil
- Federal University of São Paulo (UNIFESP), Brazil
- Interdepartmental Center for Health Economics (CRIDES), Brazil
- The National Center for Excellence in Health Technology (CENETEC), Mexico

CONFERENCE PROGRAM PLANNING COMMITTEE

Planning Committee Co-Chairs

Federico Augustovski, MD, MS, PhD, Director, Economic Evaluations and HTA Department, Institute for Clinical Effectiveness and Health Policy (IECS), Professor, Public Health, University of Buenos Aires, and Staff Physician, Family and Community Medicine Division, Italian Hospital of Buenos Aires, Buenos Aires, Argentina
Guillermo Williams, MD, Director, National Board of Health Regulation and Quality Health Care, Ministry of Health, Buenos Aires, Argentina

Issue Panel Review Committee Co-Chairs

Rafael Alfonso, MD, MSc, Scientific Director, Surgical Outcomes Research Center & Comparative Effectiveness Translation Network & Research Assistant Professor, Department of Surgery, University of Washington, Seattle, WA, USA

Pedro Lovato, MD, MPH, MA, Medical Affairs Manager, Pfizer, Inc., San José, Costa Rica

Workshop Review Committee Co-Chairs

Giácomo Balbinotto Neto, PhD, Professor, Economic Regulations, Federal University of Rio Grande do Sul, Porto Alegre, Brazil

Alarico Rodriguez, MD, Medical Benefits Manager, Uruguayan National Agency for Highly Specialized Medical Procedures, Montevideo, Uruguay

Research Review Committee Co-Chairs

Iris Contreras, MD, MSc, Clinical Researcher/Internist, Department of Internal Medicine, Hospital General de Zona No. 1-A "Dr. Rodolfo Antonio de Muchas Macías," Mexican Institute of Social Security, Mexico City, Mexico
Manuel Antonio Espinoza, MD, MSc, PhD, Department of Public Health, Catholic University of Chile and Scientific Advisor, Institute of Public Health, Santiago, Chile

EARLY REGISTRATION DEADLINE:
23 JULY 2013

RESEARCH POSTER PRESENTATIONS

POSTER PRESENTATIONS SESSION I: FRIDAY, 13 SEPTEMBER

Display Hours: 8:30-20:00

Poster Author Discussion Hour: 18:30-19:30

POSTER PRESENTATIONS SESSION II: SATURDAY, 14 SEPTEMBER

Display Hours: 8:30-15:45

Poster Author Discussion Hour: 13:30-14:30

VENUE INFORMATION/ HOTEL RESERVATIONS

Hilton Buenos Aires

Av Macacha Güemes 351
Puerto Madero, Buenos Aires, C1106BKG
Argentina

The Hilton Buenos Aires is located approximately 32 km (20 miles) from the Ezeiza Ministro Pistarini International Airport (EZE) and approximately 9 km (6 miles) from the Aeroparque Jorge Newbery Airport (AEP), which serves mostly domestic and regional flights. The discounted room rate for ISPOR conference attendees is US \$229 for single occupancy and US \$239 for double occupancy, plus applicable taxes. The discounted room rate is available for the dates of 8-17 September 2013, for reservations made before 13 August 2013 (subject to availability). **To make a reservation:** Please use the Hilton Buenos Aires online reservation system available at: www.ispor.org.

FOR FURTHER INFORMATION VISIT:
WWW.ISPOR.ORG

ISPOR 4TH LATIN AMERICA CONFERENCE

12-14 SEPTEMBER 2013 • BUENOS AIRES, ARGENTINA

SHORT COURSES • 12 SEPTEMBER 2013

SEPARATE SHORT COURSE REGISTRATION REQUIRED • SEE REGISTRATION FORM FOR DETAILS

ALL DAY COURSES (8:00-17:00)

INTRODUCTION TO HEALTH ECONOMICS FOR DECISION MAKERS

(Presented in Spanish)

TRACK: Economic Methods

LEVEL: Introductory. This course is suitable for those with little or no experience with pharmacoeconomics.

FACULTY: Diego Rosselli, MD, MEd, MHP, Associate Professor of Health Economics, Javeriana Papal University, Bogotá, Colombia; Andrés Pichon-Riviere, MD, MSc, PhD, Executive Director, Health Technology Assessment and Economic Evaluations, Institute for Clinical Effectiveness and Health Policy (IECS), and Professor of Public Health, University of Buenos Aires, Buenos Aires, Argentina

COURSE DESCRIPTION: This course is designed to teach clinicians and new researchers how to incorporate pharmacoeconomics/health economics into study design and data analysis. Participants will learn how to collect and calculate the costs of different alternatives, how to determine the economic impact of clinical outcomes, and how to identify, track, and assign costs to different types of health care resources used. The development of economic protocols and data collection sheets will be discussed. Different health economics models and techniques such as cost-minimization, cost-of-illness, cost-effectiveness, cost-benefit, and cost-utility analysis will be used along with case studies. Decision analysis, sensitivity analysis, and discounting will also be demonstrated and practiced. Participants will learn to compare and evaluate interventions such as drugs, devices, and clinical services.

INTRODUCTION TO MODELING

(Presented in Spanish)

TRACK: Modeling Methods

LEVEL: Introductory. This introductory course requires a basic familiarity with decision analysis.

FACULTY: Federico Augustovski, MD, MSc, PhD, Director, Economic Evaluations and HTA Department, Institute for Clinical Effectiveness and Health Policy (IECS), Professor, Public Health, University of Buenos Aires, and Staff Physician, Family and Community Medicine Division, Italian Hospital of Buenos Aires, Buenos Aires, Argentina; J. Jaime Caro, MD, MSc, FRCP, FACP, Adjunct Professor of Medicine, Adjunct Professor of Epidemiology and Biostatistics, McGill University, Montreal PQ, Canada; Andrés Pichon-Riviere, MD, MSc, PhD, Executive Director, Health Technology Assessment and Economic Evaluations, Institute for Clinical Effectiveness and Health Policy (IECS), and Professor of Public Health, University of Buenos Aires, Buenos Aires, Argentina; Sebastián García Martí, MD, MSc, Health Technology Assessment & Economic Evaluation, IECS, Buenos Aires, Argentina

COURSE DESCRIPTION: This course includes a review of Markov models, discrete event models, and other modeling techniques and their appropriate applications, and will review the seven ISPOR Good Research Papers in Modeling Methods published in 2012 (<http://www.ispor.org/workpaper/Modeling-Good-Research-Practices-Overview.asp>). Using a series of related examples, the course will carefully review the practical steps involved in developing and using these kinds of models. Instructors will cover the practical steps involved in the selection and modeling of data inputs and practical aspects related to the determination of when, why and how to handle stochastic (i.e., first order Monte Carlo Simulations) and probabilistic uncertainty (i.e., second order Monte Carlo Simulations).

MORNING COURSES (8:00-12:00)

EXTRACTING COST DATA FOR ECONOMIC ANALYSIS IN LATIN AMERICA

(Presented in Spanish)

TRACK: Economic Methods

LEVEL: Intermediate. This course is designed for those with some experience with pharmacoeconomic analysis.

FACULTY: Nelson Alvis Guzmán, MD, MPH, PhD, Professor & Director, Health Economics Research Group (GIES), School of Economic Sciences, University of Cartagena and Director, Center for Research and Teaching (CID), Napoleón Franco Pareja Children's Hospital, Cartagena, Colombia; Ximena Burbano-Levy, MD, International Research Director, Zilonis, Inc., Boca Raton, FL, USA; Heidy Cáceres, MD, MSc, Market Access Manager, Biopas Laboratories, Bogotá, Colombia

COURSE DESCRIPTION: This course will focus on practical aspects of cost development for pharmacoeconomic studies in order to help the participant bridge the gap between understanding pharmacoeconomic theory and the practice of developing cost estimates. Factors to consider when costing pharmacoeconomic analyses, such as perspective, data sources, data classification

systems, developing resource use profiles, obtaining unit costs, and making cost adjustments, will be presented. Examples of issues encountered when identifying and extracting cost data will be discussed.

HEALTH-RELATED QUALITY OF LIFE / UTILITY MEASURES

(Presented in Spanish)

TRACK: Patient-Reported Outcomes / Preference Methods

LEVEL: Introductory/Intermediate. This course is for those with some experience with quality-of-life measures in health economic evaluation.

FACULTY: Rafael Alfonso, MD, MSc, Scientific Director, Surgical Outcomes Research Center & Comparative Effectiveness Translation Network and Research Assistant Professor, Department of Surgery, University of Washington, Seattle, WA, USA; Hermilo Arturo Cabra, MSc, Senior Market Access Manager (Global), Global Strategic Marketing, Ethicon Endo-Surgery, Inc., Cincinnati, OH, USA

COURSE DESCRIPTION: Utility measurement is a method of determining an individual's preference for a certain outcome represented by a quantitative score (utility). During this course, methods for measuring preference-based outcomes like the standard gamble, time trade-off, and visual analogue scale will be demonstrated. Additionally, utility-based instruments (EQ-5D, HUI, QWQ, SF-36) will be briefly discussed. Utility measurement, however, is not only about mastering these techniques; it is about using them in such a way that health care decision makers can apply the results, for instance, in cost per QALY-analyses. For this purpose, one needs to be aware of shortcomings of the available utility measures and potential solutions. Furthermore, one should be aware of the decision-making context and the way results are interpreted. To equip participants with expertise in the field of utility measurement, the most important issues will be discussed. For instance, the course will consider potential insensitivity of generic instruments for particular disease-specific problems and discuss to what extent adaptation of generic or disease-specific quality of life instruments may offer a solution. Also, the issue of "whose values count: patient values or values from the general public?" will be discussed. Finally, the course will examine interpretation in the context of resource allocation.

AFTERNOON COURSES (13:00-17:00)

APPLIED MODELING

(Presented in Spanish)

TRACK: Modeling Methods

LEVEL: Advanced

PREREQUISITE: This course is suitable for those who are familiar with modeling methods and/or those who have previously taken the ISPOR short course, "Introduction to Modeling."

FACULTY: Manuel Antonio Espinoza, MD, MSc, PhD, Department of Public Health, Catholic University of Chile and Scientific Advisor, Department of Scientific Affairs, Institute of Public Health of Chile, Santiago, Chile; Mark Sculpher, PhD, MSc, Professor of Health Economics, Centre for Health Economics, University of York, Heslington York, UK; Andrew Briggs, DPhil, MSc, William R Lindsay Chair of Health Economics, Health Economics & Health Technology Assessment, Institute of Health & Wellbeing, University of Glasgow, Glasgow, UK; Pedro Saramago, MSc, Research Fellow, University of York, Centre for Health Economics, Heslington, York, UK

COURSE DESCRIPTION: This course provides a hands-on introduction to the use of software in the creation and analysis of cost-effectiveness decision models. The basics of cost-effectiveness decision making, building, and analyzing a simple decision tree will be discussed. Markov modeling and Monte Carlo simulation will be introduced. All participants must bring a Windows laptop computer with Microsoft Excel® installed and running. You will be provided download and installation instructions when you pre-register for the course.

BUDGET IMPACT ANALYSIS

(Presented in English with simultaneous Spanish & Portuguese interpretation)

TRACK: Economic Methods

LEVEL: Intermediate. This course is designed for those with some experience with pharmacoeconomic analysis.

FACULTY: C. Daniel Mullins, PhD, Professor & Chair, Pharmaceutical Health Services Research, University of Maryland School of Pharmacy, Baltimore, MD, USA

COURSE DESCRIPTION: This course will describe methods to determine the costs associated with a health condition and the budget impact of new technologies for that condition. The course will present incidence- and prevalence-based costing strategies. Treatment algorithms and event-based approaches will be demonstrated for disease-specific costs from different decision-maker perspectives. Both static and dynamic methods for estimating the budget impact of adding a new drug to a health plan formulary will be presented. Issues related to imputing missing data will also be discussed.

ISPOR 4TH LATIN AMERICA CONFERENCE

12-14 SEPTEMBER 2013 • BUENOS AIRES, ARGENTINA

SCHEDULE OF EVENTS

THURSDAY, 12 SEPTEMBER

8:00-17:00 PRE-CONFERENCE SHORT COURSE PROGRAM

(Separate Short Course registration required – see attached Registration Form for details)

17:15-18:15 EDUCATIONAL SYMPOSIUM

FROM INCREMENTAL COST-EFFECTIVENESS RATIO TO INCREMENTAL COST-EFFECTIVENESS RANGE: ADJUSTING THE THRESHOLD FOR LATIN AMERICAN COUNTRIES

Controversies surrounding a single incremental cost-effectiveness ratio (ICER) threshold for decision making will be the focus of this symposium. In many areas of the world, government payers consider higher thresholds for biologics, orphan drugs, and interventions used to treat rare diseases and lower thresholds for more conventional therapies. Issues and challenges surrounding implementing single versus diverse ICER thresholds for Latin American countries will be discussed with specific case studies from Brazil and Mexico. (Sponsored by Pfizer)

18:30-20:30 EDUCATIONAL SYMPOSIUM

THE ROLE OF MULTI-CRITERIA DECISION ANALYSIS (MCDA) IN HEALTH TECHNOLOGY ASSESSMENT (HTA) AND REIMBURSEMENT DECISION MAKING

Multi-Criteria Decision Analysis (MCDA) offers a comprehensive decision-making framework that allows for multi-disciplinary factors to be considered in a methodologically rigorous manner. This symposium will present the limitations of the traditional HTA approach for decision making and provide an overview of the MCDA framework. Examples of HTA decisions from various jurisdictions which use MCDA or an MCDA-type approach in tandem with traditional HTA will be showcased. (Sponsored by Amgen)

20:30-22:30 ISPOR WELCOME RECEPTION

FRIDAY, 13 SEPTEMBER

8:30-20:00 RESEARCH POSTER PRESENTATIONS - SESSION I

8:30-9:00 WELCOME ADDRESS & OPENING REMARKS

(Presented with simultaneous English-Spanish-Portuguese interpretation)

Gabriela Tannus Araújo, MBA, MSc, 2012-2014 Chair, ISPOR Latin America Consortium Executive Committee and Owner & Health Economics Director, Axia.Bio Consulting, São Paulo, Brazil

9:00-10:30 FIRST PLENARY SESSION

(Presented with simultaneous English-Spanish-Portuguese interpretation)

ASSIGNING REGIONAL PRIORITIES & THE USE OF HTA IN ECONOMIC EVALUATIONS IN LATIN AMERICA: HOW FAR HAVE WE COME?

Various initiatives currently exist in Latin America and the Caribbean at a regional level dedicated to promoting the adequate use of health care technologies. Some of these initiatives focus on the incorporation of economic evaluations using common tools for health care decision making at the country-level [Pan American Health Organization (PAHO) ProVac initiative (Promotion of Evidence-Based Decision Making for the Introduction of New & Underutilized Vaccines)], dedicated to new and under-utilized vaccines. Others bring together various health technology assessment (HTA) agencies and institutions throughout the Americas to work together as a network in advancing the diverse aspects of HTA [RedETSA (Latin America HTA Network)]. Still others concentrate on the importance of interactions between the health care system and the judicial system, since the majority of countries in Latin America guarantee health care as a universal right within their national constitutions (World Bank Institute Priority Setting and Constitutional Mandates in Health initiative). In this session, speakers will discuss the achievements and challenges of each of these regional initiatives.

Moderator: Federico Augustovski, MD, MS, PhD, Director, Economic Evaluations and HTA Department, Institute for Clinical Effectiveness and Health Policy (IECS), Professor, Public Health, University of Buenos Aires, and Staff Physician, Family and Community Medicine Division, Italian Hospital of Buenos Aires, Buenos Aires, Argentina

Speakers: Jon Andrus, MD, Deputy Director, Pan American Health Organization (PAHO), Washington, DC, USA; **Andrés Pichón Riviere, MD, MSc, PhD**, Executive Director, Institute for Clinical Effectiveness and Health Policy (IECS); Vice-Chair, International Network of Agencies for Health Technology Assessment (INAHTA); Board of Directors Member, HTAi; and Professor of Public Health, University of Buenos Aires, Buenos Aires, Argentina; **Alexandre Lemgruber, MD, MSc**, Regional Advisor, Health Technologies, Pan American Health Organization (PAHO), Washington, DC, USA; **Leonardo Cubillos, MD, MPH**, Senior Health Specialist, World Bank Institute (WBI), Washington DC, USA

10:30-11:00 BREAK, EXHIBITS & RESEARCH POSTER PRESENTATIONS VIEWING - SESSION I

11:00-12:00 ISSUE PANELS - SESSION I

IP1: EVALUACIÓN ECONÓMICA EN LATINOAMÉRICA: ¿EL ANÁLISIS DE COSTO-EFECTIVIDAD RESPONDE NUESTRAS NECESIDADES? (Presented in Spanish)

Moderator: Federico Augustovski, MD, MSc, PhD, Institute for Clinical Effectiveness and Health Policy (IECS) and University of Buenos Aires, Buenos Aires, Argentina

Panelists: Guillermo Melendez, MD, MSc, Fundación Mexicana para la Salud AC, Mexico D.F., Mexico; **Manuel Antonio Espinoza, MD, MSc, PhD**, Pontificia Universidad Católica de Chile, Santiago, Chile; **Marcelo Fonseca, MD, MSc**, Universidade Federal de São Paulo, São Paulo, Brazil

IP2: COST-EFFECTIVENESS OF MRI IN THE EARLY DETECTION OF BREAST CANCER RECURRENCE IN PATIENTS UNDERGOING TREATMENT WITH CONSERVATIVE SURGERY: IS IT FEASIBLE IN LATIN AMERICA? (Presented in English)

Moderator: Elide Sbardello Mariano da Costa, MD, Curitiba City Health Institute, Curitiba, Brazil

Panelists: Adriano Hyeda, MD, Santa Casa de Misericórdia Hospital, Curitiba, Paraná, Brazil; **Elio Tanaka, MD**, Curitiba City Health Institute, Curitiba, Brazil

IP3: WHAT IS THE ECONOMIC LANDSCAPE OF BIOSIMILARS IN LATIN AMERICA? (Presented in Spanish)

Moderator: Andrea Puig, PhD, Johnson and Johnson World Headquarters, New Brunswick, NJ, USA

Panelists: Gilberto Castañeda, PhD, Instituto Politecnico Nacional, Mexico D.F., Mexico; **Ricardo García, PhD**, Centro Latinoamericano de Expertos en Investigación de Biológicos (CLAPBio), Rio de Janeiro, Brazil; **Eduardo Fabián Mysler, MD**, Organización Médica de Investigación, Buenos Aires, Argentina

IP4: APLICACIÓN DE LA EVIDENCIA DE COSTO-EFECTIVIDAD Y COSTO-UTILIDAD A LOS PROCESOS DE TOMA DE DECISIÓN SOBRE PRECIO Y COBERTURA DE NUEVOS MEDICAMENTOS. ¿EXISTE UN UMBRAL DE COSTO-EFECTIVIDAD EN LATINOAMÉRICA? (Presented in Spanish)

Moderator: Andrés Pichon Riviere, MD, MSc, PhD, Institute for Clinical Effectiveness and Health Policy (IECS), Buenos Aires, Argentina

Panelists: Clarice Petramale, PhD, Brazilian Ministry of Health, Brasília, Brazil; **Marianela Castillo, MSc**, Ministerio de Salud de Chile, Santiago, Región Metropoli, Chile; **Pedro Rizo Ríos, MD**, Consejo de Salubridad General, Mexico D.F., Mexico

IP5: WHAT ARE THE IMPLICATIONS OF GENERIC DRUG POLICIES FOR HEALTH CARE SYSTEMS AND INDIVIDUAL PATIENTS IN LATIN AMERICA? (Presented in English)

Moderator: Anke-Peggy Holtorf, PhD, MBA, Health Outcomes Strategies GmbH, Basel, Switzerland

Panelists: Rafael Alfonso-Cristancho, MD, MSc, University of Washington, Seattle, WA, USA; **Marcos Bosi Ferraz, MD, PhD**, Universidade Federal de São Paulo, São Paulo, Brazil

SCHEDULE OF EVENTS

12:00-15:00 LUNCH, EXHIBITS & RESEARCH POSTER PRESENTATIONS VIEWING - SESSION I

12:30-13:30 EDUCATIONAL SYMPOSIUM

HEALTH TECHNOLOGY ASSESSMENT VS. INTERNATIONAL REFERENCE PRICING IN LATIN AMERICA

During the last decade, Latin American countries have started to adopt different mechanisms to value innovation. In some countries, the health technology assessment (HTA) framework has been developed in parallel with international reference pricing (IRP). This symposium will discuss HTA and IRP, how they interact, and the implications of parallel use in the way countries/health systems assess the value of innovation.

(Sponsored by Merck Sharp & Dohme)

13:45-14:45 EDUCATIONAL SYMPOSIUM

MANAGING DIABETES IN LATIN AMERICA – THE ROLE OF INNOVATIVE MEDICINES

The management of diabetes is a key clinical and economic concern globally. This symposium will evaluate the clinical and economic elements of diabetes management in Latin America, and challenge current ideas on the role of innovative medicines to manage the disease in Latin America. (Sponsored by Eli Lilly and Company)

15:00-16:00 WORKSHOPS - SESSION I

W1: ADAPTING GLOBAL PHARMACOECONOMIC MODELS TO THE LATIN AMERICAN CONTEXT – KEY CHALLENGES AND CONSIDERATIONS (Presented in English)

Discussion Leaders: Michael Drummond, PhD, University of York and OptumInsight, Heslington, York, UK; Ximena Burbano-Levy, MD, Zilonis Health, Inc., Boca Raton, FL, USA; Jennifer Haig, BSc, Optum, Burlington, ON, Canada

W2: HOW TO HANDLE THE LACK OF INFORMATION IN EMERGING MARKETS: A LIST OF OPPORTUNITIES FROM LATIN AMERICA (Presented in Spanish)

Discussion Leaders: C. Daniel Mullins, PhD, University of Maryland School of Pharmacy, Baltimore, MD, USA; Rafael Alfonso, MD, MSc, University of Washington, Seattle, WA, USA; Gerardo Machnicki, MSc, PhD, Novartis Latin America & Canada, Buenos Aires, Argentina

W3: PRICING AND REIMBURSEMENT SCHEMES: IS VALUE-BASED PRICING A FEASIBLE POLICY IN LATIN AMERICAN COUNTRIES? (Presented in Spanish)

Discussion Leaders: Manuel Antonio Espinoza, MD, MSc, PhD, Pontificia Universidad Católica de Chile, Santiago, Chile; Carla Castillo, MSc, Departamento de Metodologías, Ministerio de Desarrollo Social, Santiago, Chile; Nicolas Silva, MD, Universidad de Chile, Santiago, Chile; Mark J. Sculpher, MSc, PhD, University of York, Heslington, York, UK

W4: TOMA DE DECISIONES EN SALUD: UNA MIRADA DE INVESTIGADORES Y DECISORES DESDE EL INSTRUMENTO EVIDEM (Presented in Spanish)

Discussion Leaders: Luis Alberto Vera-Benavides, MD, MEBPH, Universidad Autónoma de Chile, Talca, Chile; Claudio A. Méndez, MPH, Universidad Austral de Chile, Valdivia, Chile; Clarice Petramale, PhD, Brazilian Ministry of Health, Brasília, Brazil

W5: COMO MEDIR UTILIDADE E ENVOLVER O PÚBLICO NO PROCESSO DE AVALIAÇÃO DE TECNOLOGIAS DE SAÚDE (Presented in Portuguese)

Discussion Leaders: Marisa S. Santos, MD, Núcleo de Avaliação de Tecnologias em Saúde, Instituto Nacional de Cardiologia, Rio de Janeiro, Brazil; Helena Cramer V. Rey, MD, MSc, Brazilian Ministry of Health, Rio de Janeiro, Brazil; Monica A. de C T Cintra, MD, MSc, Brazilian Ministry of Health, Rio de Janeiro, Brazil; Aline Silveira Silva, MSc, Brazilian Ministry of Health, Brasília, Brazil

16:00-16:15 BREAK, EXHIBITS & RESEARCH POSTER PRESENTATIONS VIEWING - SESSION I

16:15-17:15 RESEARCH PODIUM PRESENTATIONS - SESSION I

BUDGET IMPACT STUDIES (BU1 and BU3 presented in Spanish; BU2 and BU4 presented in Portuguese)

BU1: TREATMENT OF TYPE-2 DIABETES WITH SAXAGLIPTIN/METFORMIN EXTENDED-RELEASE (XR): BUDGET IMPACT ANALYSIS IN ARGENTINA
Elgart J¹, Gonzalez L¹, Aiello EC², Gagliardino JJ¹, CENEXA - Centro de Endocrinología Experimental y Aplicada (UNLP-CONICET La Plata), La Plata, Buenos Aires, Argentina, ²Bristol-Myers Squibb, Buenos Aires, Argentina

BU2: ANÁLISE DE IMPACTO ORÇAMENTÁRIO: QUANTO CUSTARIA AO SISTEMA PÚBLICO DE SAÚDE BRASILEIRO INCREMENTAR, POR MEIO DE TRANSPLANTES, O TRATAMENTO DA DOENÇA RENAL CRÔNICA TERMINAL?

Alvares J, Falleiros DR, Barbosa MM, Almeida AM, Araujo VE, Guerra Junior AA, Cherschiglia ML, Acurcio FDA, Universidade Federal de Minas Gerais, Belo Horizonte, Brazil

BU3: COSTO E IMPACTO PRESUPUESTAL DEL TRATAMIENTO DE LA ARTRITIS REUMATOIDE MODERADA Y SEVERA CONSIDERANDO EL USO DE TERAPIAS BIOLÓGICAS EN MÉXICO

Aguirre A¹, Peniche-Otero G², Jiménez I², Baeza G², Muciño-Ortega E³, Galindo-Suárez RM³, ¹UCB de Mexico, S.A. de C.V., México D.F., Mexico, ²Customized Premium Products S.A. de C.V., Mexico City, Mexico, ³Pfizer S.A. de C.V., México D.F., Mexico

BU4: BUDGET IMPACT ANALYSIS OF ABIRATERONE ACETATE IN METASTATIC CASTRATION-RESISTANT PROSTATE CANCER PATIENTS PREVIOUSLY TREATED WITH DOCETAXEL FROM THE PERSPECTIVE OF THE BRAZILIAN PRIVATE HEALTH CARE SYSTEM

Vitale V, Asano E, Pereira ML, Janssen Cilag Farmaceutica, São Paulo, Brazil

CARDIOVASCULAR DISEASE OUTCOMES RESEARCH (Presented in Spanish)

CV1: UTILIDAD DE BIOMARCADORES CARDIACOS (POINT OF CARE TESTING) EN EL ÁREA DE URGENCIAS Y SU IMPACTO ECONOMICO

Contreras I¹, Lopez-Perez A², Mendez GF³, Mejia-Arangure E⁴, ¹Instituto Mexicano del Seguro Social, México D.F., Mexico, ²Instituto Mexicano del Seguro Social, Los Reyes La Paz, Mexico, ³Instituto Mexicano del Seguro Social, Jalapa, Mexico, ⁴HOS Health Outcomes Solutions S.A de C.V., México D.F., Mexico

CV2: ESTIMATION OF THE COST-EFFECTIVENESS OF APIXABAN IN NON-VALVULAR ATRIAL FIBRILLATION IN ARGENTINA

Giorgi MA¹, Caroli C², Micono P³, Giglio ND⁴, Aiello EC⁵, Donato BMK⁶, Mould JF⁷, Radero G⁸, Casas M⁸, ¹CEMIC, Buenos Aires, Argentina, ²FLENI, Buenos Aires, Argentina, ³Universidad Austral, Buenos Aires, Argentina, ⁴Hospital de Niños Ricardo Gutierrez, Buenos Aires, Argentina, ⁵Bristol-Myers Squibb, Buenos Aires, Argentina, ⁶Bristol-Myers Squibb, Wallingford, CT, USA, ⁷Pfizer, Inc., New York, NY, USA, ⁸Pfizer, Inc., Buenos Aires, Argentina

CV3: PULSE PRESSURE AND STROKE RISK: DEVELOPMENT AND VALIDATION OF A STROKE RISK EQUATION

Ayyagari R¹, Vekeman F², Lefebvre P², Ong SH³, Faust E¹, Trahey A¹, Machnicki G⁴, Duh MS¹, ¹Analysis Group, Inc., Boston, MA, USA, ²Groupe d'analyse, Ltée, Montréal, QC, Canada, ³Novartis Pharma AG, Basel, Switzerland, ⁴Novartis Latin America & Canada, Buenos Aires, Argentina

CV4: ANÁLISIS DE COSTO-EFECTIVIDAD DEL USO DE ESTATINAS EN LA PREVENCIÓN DE EVENTOS CARDIOVASCULARES EN COLOMBIA

Mould J¹, Ordoñez J², Gutierrez-Ardila MV³, Vargas Zea N³, ¹Pfizer, Inc., New York, NY, USA, ²Universidad CES, Medellín, Colombia, ³Pfizer S.A.S., Bogotá, Colombia

HEALTH CARE EXPENDITURE STUDIES (HC1, HC2, HC4 presented in Spanish; HC3 presented in English)

HC1: ADDRESSING CHILDHOOD OBESITY IN MEXICO: SAVINGS ON HEALTH CARE EXPENDITURES FROM REGULATING FOOD AND BEVERAGE SALES IN BASIC EDUCATION SCHOOLS

Guajardo V¹, Gutierrez C¹, Rivera G², ¹Instituto Mexicano del Seguro Social, México D.F., Mexico, ²Secretaría de Salud, México D.F., Mexico

HC2: EFFECT OF HEALTH SPENDING, INCOME INEQUALITY AND MARGINATION INDEX ON THE EFFICIENCY OF THE HEALTH SYSTEM IN MEXICO

Pinzon Florez CE¹, Reveiz L², Idrovo AJ³, Reyes H⁴, Diaz de Leon C¹, ¹Instituto Nacional de Salud Pública, Cuernavaca, Mexico, ²Organización Panamericana de la Salud, Washington, Mexico, ³Fundacion Cardiovascular de Colombia, Bucaramanga, Colombia

HC3: PAYERS' AND PHYSICIANS' EVIDENCE AND DISCOUNT EXPECTATIONS FOR BIOSIMILARS IN SIX LATIN AMERICAN COUNTRIES

Sandorff E¹, Severi Bruni D², Halbert R³, ¹ICON, Blue Bell, PA, USA, ²ICON, El Segundo, CA, USA, ³ICON, PriceSpective LLC, El Segundo, CA, USA

HC4: ANÁLISIS DE COSTO-EFECTIVIDAD DE LAS VACUNAS NEUMOCÓCICAS 13-VALENTE Y 23-VALENTE PARA ADULTOS DE ALTO RIESGO EN COLOMBIA

Ordoñez Molina JE¹, Gutierrez-Ardila MV², Vargas Zea N², ¹CES University, Medellín, Colombia, ²Pfizer S.A.S., Bogotá, Colombia

HEALTH TECHNOLOGY ASSESSMENT STUDIES (HT1, HT3, HT4 presented in Portuguese; HT2 presented in English)

HT1: EFFICACY AND SAFETY OF NEW ANTICOAGULANTS IN THE TREATMENT OF ATRIAL FIBRILLATION: A HEALTH TECHNOLOGY ASSESSMENT

Buehler AM, Suzumura EA, Figueiró MF, Cavalcanti AB, Berwanger O, Hospital do Coração, São Paulo, Brazil

SCHEDULE OF EVENTS

HT2: HEALTH TECHNOLOGY ASSESSMENT REPORT FOR POSITRON EMISSION TOMOGRAPHY IN PATIENTS WITH CANCER

Alcaraz A, Meza V, Glujovsky D, Romano M, Morelli D, Comandé D, Garcia Marti S, Pichon Riviere A, Augustovski F, Institute for Clinical Effectiveness and Health Policy (IECS), Buenos Aires, Argentina

HT3: FORMULATIONS OF AMPHOTERICIN B FOR THE TREATMENT OF FUNGAL INFECTIONS IN PATIENTS WITH HIV/AIDS

Costa JO, **Lemos LLP**, Gomes RM, Guerra Junior AA, Acurcio FA, Universidade Federal de Minas Gerais, Belo Horizonte, Brazil

HT4: EFICÁCIA E SEGURANÇA DE RANIBIZUMABE E BEVACIZUMABE NO TRATAMENTO DE DEGENERAÇÃO MACULAR RELACIONADA A IDADE

Saturnino LTM¹, Silveira MR², Guerra Junior AA³, Acurcio FDA³, ¹Instituto Nacional de Cardiologia, Rio de Janeiro, Brazil, ²Faculdade de Farmácia da Universidade Federal de Minas Gerais, Belo Horizonte, Brazil, ³Universidade Federal de Minas Gerais, Belo Horizonte, Brazil

INFECTIOUS DISEASE STUDIES (Presented in Spanish)

IN1: ASSESSMENT OF BURDEN OF ILLNESS DUE TO HERPES ZOSTER IN ARGENTINA: A PROSPECTIVE OBSERVATIONAL STUDY

Vujacich C¹, de Wouters L², Margari A³, Gordóvil M², Kawai K⁴, Lemos E⁵, Rampakakis E⁶, Pollock C⁷, White R⁸, Acosta CJ⁸, Sampalis JS⁹, ¹Fundación Centro de Estudios Infectológicos (FUNCEI), Buenos Aires, Argentina, ²Hospital Privado de la Comunidad, Mar del Plata, Argentina, ³Hospital Naval, Buenos Aires, Argentina, ⁴Merck/Temple University, Philadelphia, PA, USA, ⁵MSD Colombia, Bogota, Colombia, ⁶McGill University & JSS Medical Research, St. Laurent, QC, Canada, ⁷JSS Medical Research, St. Laurent, QC, Canada, ⁸Merck & Co., West Point, PA, USA

IN2: COSTO-EFECTIVIDAD DEL USO DE PRUEBAS TREPONÉMICAS RÁPIDAS PARA LA DETECCIÓN Y TRATAMIENTO TEMPRANO DE SÍFILIS GESTACIONAL EN COLOMBIA

Castañeda Guerrero C¹, Eslava J¹, Ruiz A¹, Diaz J¹, Prieto V¹, Lemos EV², ¹National University of Colombia, Bogota, Colombia, ²Fundacion para el Desarrollo y Apoyo en Salud Internacional (FUDASAI), Bogotá, Colombia

IN3: ANÁLISIS COSTO EFECTIVIDAD DE INTERVENCIONES PARA EL MANEJO DEL TRASTORNO DEPRESIVO MAYOR (TDM) EN PACIENTES CON VIRUS DE LA INMUNODEFICIENCIA HUMANA (VIH+) QUE INICIAN TRATAMIENTO ANTIRRETROVIRAL DE GRAN ACTIVIDAD (TARGA)

Lemus F, National Institute of Public Health, Naucalpan, Mexico

IN4: COSTO-EFECTIVIDAD DE TRES ESTRATEGIAS DIAGNÓSTICAS PARA LA IDENTIFICACIÓN DE INFECCIÓN BACTERIANA SEVERA EN LACTANTES FEBRILES SIN FOCO

Buendía JA¹, Urman G², Urman E², Grosman A², ¹Universidad de Antioquia, Medellín, Colombia, ²Universidad Maimonides, Buenos Aires, Argentina

17:30-18:30 RESEARCH PODIUM PRESENTATIONS - SESSION II

CANCER OUTCOMES RESEARCH (CA1 and CA3 presented in Spanish; CA2 presented in Portuguese; CA4 presented in English)

CA1: IMPLICATIONS OF GLOBAL PRICING POLICIES OF PHARMACEUTICALS TO ACCESS INNOVATIVE DRUGS: THE CASE OF TRASTUZUMAB IN SEVEN LATIN AMERICAN COUNTRIES

Pichon Riviere A¹, Garay U¹, Augustovski F¹, Vallejos C², Huayanay L³, Navia MDP⁴, Rodríguez A⁵, Oliveira C⁶, Andrade CJ⁷, Buendía JA⁸, ¹Institute for Clinical Effectiveness and Health Policy (IECS), Buenos Aires, Argentina, ²Universidad de La Frontera, Temuco, Chile, ³Universidad Peruana Cayetano Heredia, Lima, Peru, ⁴Universidad de San Andres, La Paz, Bolivia, ⁵Fondo Nacional de Recursos, Montevideo, Uruguay, ⁶ANVISA, Brasilia, Brazil, ⁷INC, Rio de Janeiro, Brazil, ⁸University of Antioquia, Medellín, Colombia

CA2: NATIONAL SPENDING WITH SCREENING, DIAGNOSIS, AND TREATMENT OF CERVICAL CANCER: ESTIMATES BASED ON HEALTH INFORMATION SYSTEMS IN BRAZIL, 2006

Novaes HMD¹, **De Soarez PC**¹, Itria A², azevedo e Silva G³, Sartori AMC⁴, Rama C⁵, ¹University of Sao Paulo, Sao Paulo, Brazil, ²Universidade Federal de Goiás - Pesquisador do Instituto de Avaliação de Tecnologia em Saúde (IATS), Goiânia, Brazil, ³Universidade Estadual do Rio de Janeiro, Rio de Janeiro, Brazil, ⁴University of Sao Paulo, Sao Paulo, Brazil, ⁵Secretaria do Estado de Saúde de São Paulo, São Paulo, Brazil

CA3: ANÁLISIS DE COSTO-EFECTIVIDAD DE ESTRATEGIAS DE PREVENCIÓN PRIMARIA Y SECUNDARIA PARA CÁNCER DE CUELLO UTERINO EN COLOMBIA

Gamboia OA, Murillo RH, González M, Instituto Nacional de Cancerología, Bogotá, Colombia

CA4: EMERGING CARDIOVASCULAR EVENTS ASSOCIATED WITH TARGETED ANTICANCER DRUGS: PRELIMINARY RESULTS OF A CARE LINE'S PROGRAM BASED ON AUDIT VIGILANCE IN A PRIVATE HEALTH CARE IN BRAZIL

Tanaka E¹, DA Costa ESM², Santos GL², Michaelis W², Miguel Neto C², Ribas KMDG², Mischiatti E², Kotze OH², ¹Curitiba City Health Institute, Curitiba, Brazil, ²ICS, Curitiba, Brazil

FORMULARY DEVELOPMENT AND PUBLICATION OF COST STUDIES (FD1, FD2, FD3 presented in Spanish; FD4 presented in Portuguese)

FD1: RESULTADOS DE LA ENCUESTA "CHANGE PAIN" LATINOAMERICANA: DIAGNÓSTICO Y TRATAMIENTO ACTUAL DE LOS PACIENTES CON DOLOR CRÓNICO

Amescua C¹, Berenguel M¹, Silvan R², ¹Grunenthal, Latinoamérica, México D.F., Mexico, ²Independent Consultant, México D.F., Mexico

FD2: ESSENTIAL MEDICINE LIST (CUADRO BÁSICO) IN MÉXICO: IS IT A GUIDELINE FOR DECISION MAKING ON THE CURRENT AND FUTURE HEALTH NEEDS?

Lemus A¹, Marquez R¹, Jimenez P², ¹Universidad de La Salle, México D.F., Mexico, ²Independent Consultant, México D.F., Mexico

FD3: ¿PUEDE UN CAMBIO DEL 2003 EN EL REGLAMENTO EN EL CUADRO BÁSICO (CBM) EN MÉXICO IMPACTAR LA CANTIDAD DE ESTUDIOS CIENTÍFICOS PUBLICADOS DE EVALUACIÓN ECONÓMICA COMPLETOS DE MEDICAMENTOS (EEMC) EN LOS ÚLTIMOS 10 AÑOS?

Márquez Cruz M¹, Peralta Bácnas LA¹, Ibarra Cázares AE¹, Rodríguez Mendoza MM¹, Pizarro Castellanos M², Soto Molina H¹, ¹Universidad Autónoma Metropolitana, México D.F., Mexico, ²Hospital Infantil Federico Gomez, México D.F., Mexico

FD4: EVALUACIÓN ECONÓMICA EN LA SALUD: UNA REVISIÓN SOBRE LAS PUBLICACIONES EN BRASIL

Souza RM¹, Teixeira M², ¹Fundação Osvaldo Cruz, Salvador, Brazil, ²Health Secretary of the State of Bahia, Salvador, Brazil

PRICING STUDIES (Presented in Spanish)

PR1: ANÁLISIS DEL IMPACTO EN LA DEMANDA DE TECNOLOGÍAS INCLUIDAS EN EL PLAN DE BENEFICIOS COLOMBIANO (POS) POSTERIOR A SU ACTUALIZACIÓN EN 2012

Romero M¹, Acero G¹, Marrugo R¹, Alvis N², Arango C¹, ¹Fundacion Salutia, Bogotá, Colombia, ²Universidad de Cartagena, Cartagena de Indias, Bolívar, Colombia

PR2: ECONOMIC EVALUATION OF AN URINE CLOSED COLLECTION SYSTEM VERSUS A TRADITIONAL OPEN DEVICE IN NON-PREGNANT WOMEN

Cardona DP¹, Burbano-Levy X², Palacios E³, Zapata L³, ¹Universidad de Antioquia-Facultad De Quimica Farmaceutica, Medellín, Colombia, ²Zilonis Health, Inc., Boca Raton, FL, USA, ³Guia Mark, S. A. de C. V., México D.F., Mexico

PR3: ANÁLISIS COSTO-EFECTIVIDAD DE LINEZOLID COMPARADO CON VANCOMICINA EN EL MANEJO DE LA NEUMONÍA ASOCIADA A LA VENTILACIÓN MECÁNICA EN COLOMBIA

Varon FA¹, Londoño D², Álvarez C², Taborda A², Prieto Martinez V³, ¹Fundación Neumológica Colombiana, Bogotá, Colombia, ²Pontificia Universidad Javeriana, Bogotá, Colombia, ³Pfizer S.A.S., Bogotá, Colombia

PR4: ESTUDIO TRANSVERSAL DEL PROCESO DE ACTUALIZACIÓN DE MEDICAMENTOS EN EL CUADRO BÁSICO Y CATÁLOGO DE INSUMOS DEL SECTOR SALUD

Rizo Ríos P, González Rivera A, Rivas Oropeza I, Rivas Bocanegra R, Melchor Martínez F, Ruíz Pérez LC, Consejo de Salubridad General, México D.F., Mexico

COST, RISK FACTOR, & UNIVERSAL COVERAGE STUDIES (RF1, RF2, RF3 presented in Spanish; RF4 presented in Portuguese)

RF1: EFECTO DEL SEGURO POPULAR SALUD SOBRE LA DEMANDA DE SERVICIOS PRENATALES EN EL CONTEXTO DE LA COBERTURA UNIVERSAL, MÉXICO 2012

Servan-Mori E, National Institute of Public Health, Cuernavaca, Mexico

RF2: EPIDEMIOLOGICAL AND ECONOMIC IMPACT OF CHRONIC KIDNEY DISEASE IN PATIENTS WITH HYPERTENSION AND DIABETES IN COLOMBIA

Carrasquilla-Sotomayor M, Santos-Ochoa JJ, Alvis-Zakzuk J, Alvis-Zakzuk N, Paternina-Caicedo A, **Alvis-Guzmán N**, Universidad de Cartagena, Cartagena de Indias, Colombia

RF3: FACTORES PREDICTORES DE OBSTRUCCIONES CORONARIAS SIGNIFICATIVAS EN PACIENTES ADULTOS CON CINEANGIOCORONARIOGRAFÍAS REALIZADAS EN URUGUAY FINANCIADAS POR EL FONDO NACIONAL DE RECURSOS

Fernandez G, Morales M, Lombide I, Perna A, Fondo Nacional de Recursos, Montevideo, Uruguay

SCHEDULE OF EVENTS

RF4: COST-EFFECTIVENESS OF VARIOUS COMBINATIONS OF HUMAN PAPILLOMAVIRUS (HPV)-BASED PRIMARY SCREENING TESTING, INCLUDING GENOTYPING FOR HPV 16/18, FOR CERVICAL CANCER SCREENING IN MEXICO Corro A¹, Ramirez A¹, Williams E², Huang J³, Souza FH⁴, ¹Roche Diagnostics, Mexico City, Mexico, ²Xcenda, Palm Harbor, FL, USA, ³Roche Molecular Diagnostics, Pleasanton, CA, USA, ⁴Roche Diagnostics, Sao Paulo, Brazil

TRENDS IN HEALTH CARE STUDIES (Presented in Spanish)

TR1: SELF-REPORTED HEALTH STATUS AND EQ-5D-3L VALUES OF THE ARGENTINE POPULATION: COMPARING 2005 VERSUS 2009 NATIONAL RISK FACTOR SURVEYS Augustovski F, Rey Ares L, Gibbons L, Institute for Clinical Effectiveness and Health Policy (IECS), Buenos Aires, Argentina

TR2: ANÁLISIS BIBLIOMÉTRICO DE LA PRODUCCIÓN CIENTÍFICA EN ECONOMÍA DE LA SALUD EN LATINOAMÉRICA

Simbaqueba E¹, Romero M, Fundacion Salutia, Bogotá, Colombia

TR3: A MULTI-NATIONAL SURVEY ASSESSING THE RELATIONSHIP BETWEEN PROPHYLAXIS TREATMENT AND HEALTH-RELATED QUALITY OF LIFE AMONG SEVERE HEMOPHILIA A PATIENTS IN LATIN AMERICA

Perez Bianco PR¹, Berges A², Linares A³, Moreno B⁴, Arvizu J⁵, Brabata C⁵, Xiong Y⁶, Ito D⁶, ¹Instituto de Investigaciones Hematológicas - Academia Nacional de Medicina, Buenos Aires, Argentina, ²Instituto Mexicano del Seguro Social/Centro Medico Nacional La Raza Hospital General, Azcapotzalco, Mexico, ³Clinica Infantil Colsubsidio, Bogotá, Colombia, ⁴Fundacion Panamena de Hemofilia/Hospital del Nino, Panama City, Panama, ⁵Baxter Healthcare Corporation, Miami, FL, USA, ⁶Baxter Healthcare Corporation, Westlake Village, CA, USA

TR4: LA PROTECCIÓN FINANCIERA Y EL GASTO DE BOLSILLO EN SALUD DE LA POBLACIÓN MEXICANA 2002-2010

Rivera G¹, Guajardo V², Gutierrez C², ¹Secretaría de Salud, México D.F., Mexico, ²Instituto Mexicano del Seguro Social, México D.F., Mexico

18:30-19:30 RESEARCH POSTER AUTHOR DISCUSSION HOUR - SESSION I

18:30-20:00 RESEARCH POSTERS & EXHIBITORS' RECEPTION & RESEARCH POSTER PRESENTATIONS VIEWING - SESSION I

19:30-20:30 EDUCATIONAL SYMPOSIUM

WORKING WITH HEALTH TECHNOLOGY ASSESSMENT (HTA) IN LATIN AMERICA: CHALLENGES AND OPPORTUNITIES

Argentina, Brazil, and Mexico are at different points on the HTA development continuum, but the trajectory is similar – a move towards increased complexity in evaluations and the evidence HTA bodies need. This symposium brings together experts from industry, academia, and government to provide a 360 degree perspective on how HTA should develop in these three markets. The implications for both manufacturers and payers will be discussed. (Sponsored by Double Helix Consulting)

SATURDAY, 14 SEPTEMBER

7:45-8:45 EDUCATIONAL SYMPOSIUM

DETERMINING THE VALUE OF MEDICINE: THE PERSPECTIVE OF HTA, PUBLIC, AND PRIVATE HEALTH INSURANCE IN LATIN AMERICA

This symposium will focus on the evolving mechanisms of payment and health technology assessment in Latin America. It will cover current health care trends in the region and the rise of private health insurance coverage in Latin America. (Sponsored by Optum)

8:30-9:00 RESEARCH POSTER PRESENTATIONS VIEWING - SESSION II

9:00-10:30 SECOND PLENARY SESSION

(Presented with simultaneous English-Spanish-Portuguese interpretation)

HTA AS A TOOL TO INFORM PRICING AND COVERAGE POLICIES IN THE NATIONAL CONTEXT: CASE STUDIES FROM ARGENTINA, BRAZIL, CHILE, COLOMBIA, MEXICO, AND URUGUAY

During this plenary session, speakers will review successful case studies from select Latin America countries regarding the use of health technology assessment (HTA) at the public/government level. These countries are considered to be among those

successfully advancing towards systems where economic considerations (i.e., economic evaluations, budget impact analysis, etc.) are routinely utilized in public health care decision making. Issues discussed will include: the incorporation of health technologies into the health care system; pricing negotiations for the incorporation of new health care technologies; and the design and revision of public health care benefit packages.

Moderator: Guillermo Williams, MD, Director, National Board of Health Regulation and Quality Health Care, Ministry of Health, Buenos Aires, Argentina

Speakers: Clarice Petramale, MD, Director, Unified Health System (SUS – Sistema Único da Saúde), Ministry of Health, Brasilia, Brazil; Marianela Castillo Riquelme, MSc, Technical Coordinator, National Commission on Health Technology Assessment, Ministry of Health, Santiago, Chile; Hector Eduardo Castro Jaramillo, MD, MSc, PhD(c), Executive Director, Institute for Health Technology Assessment (IETS - Institución de Evaluación Tecnológica en Salud), Bogotá, Colombia; Eduardo González Pier, MD, PhD, MEcon, Executive Director, National Health Foundation (FUNSALUD) and former Director of Finance, Mexican Institute for Social Security (IMSS), Mexico City, Mexico; Alarico Rodríguez, MD, Medical Benefits Manager, Uruguayan National Agency for Highly Specialized Medical Procedures (FNR – Fondo Nacional de Recursos), Montevideo, Uruguay

10:30-11:00 BREAK, EXHIBITS & RESEARCH POSTER PRESENTATIONS VIEWING - SESSION II

11:00-12:00 ISSUE PANELS - SESSION II

IP6: ARE LOCAL QUALITY OF LIFE DATA NEEDED TO GUIDE REIMBURSEMENT DECISIONS IN LATIN AMERICA? (Presented in English)

Moderator: Andrew J. Lloyd, DPhil, Oxford Outcomes Ltd., an ICON PLC Company, Oxford, Oxon, UK

Panelists: Federico Augustovski, MD, MSc, PhD, Institute for Clinical Effectiveness and Health Policy (IECS) and University of Buenos Aires, Buenos Aires, Argentina; Pedro Rizo Ríos, MD, Consejo de Salubridad General, Mexico D.F., Mexico; Vijayveer Bonthapally, PhD, Millennium Pharmaceuticals Inc., Cambridge, MA, USA

IP7: ACCESS TO INNOVATIVE MEDICINES IN LATIN AMERICA – WHAT IS THE SOLUTION? (Presented in English)

Moderator: Michelle L. Sotak, MPH, MBA, Optum, Chicago, IL, USA

Panelists: Otávio Augusto Camara Clark, MD, PhD, Evidencias, Campinas, Brazil; Roberto Bitton, MD, Austral University, Vicente López, Argentina; Ximena Burbano-Levy, MD, Zilonis Health, Inc, Boca Raton, FL, USA

IP8: IS THERE SCOPE FOR MORE HARMONIZATION OF PROCEDURES FOR ASSESSING ORPHAN DRUGS IN LATIN AMERICA? (Presented in English)

Moderator: Renee J. G. Arnold, PharmD, RPh, Mount Sinai School of Medicine, New York, NY, USA

Panelists: Michelle Ann Soriano, PhD, IMS Health Mexico, Mexico City, Mexico; Dalia Mahmoud, MBA, Celgene, Summit, NJ, USA; Gabriela Tannus, MSc, Axia.Bio, Sao Paulo, Sao Paulo, Brazil

IP9: ACCESO AL MERCADO POR VIA JUDICIAL: NECESIDAD O AMENAZA? (Presented in Spanish)

Moderator: J. Jaime Caro, MDCM, FRCPC, FACP, McGill University, Montreal, QC, Canada

Panelists: Rodrigo Salinas, MD, Universidad de Chile, Santiago, Chile; Román Navarro, LL.M., Colegio de Abogados de Costa Rica, San Jose, Costa Rica; Roberto Iunes, PhD, Instituto del Banco Mundial, Washington, DC, USA

IP10: ARE WE RUNNING BEFORE WALKING WITH HEALTH TECHNOLOGY ASSESSMENT IN LATIN AMERICA? (Presented in Spanish)

Moderator: Diego Guarín, MD, MPH, Merck & Co, Inc., Mexico City, Mexico
Panelists: Leonardo Cubillos, MD, MPH, World Bank Institute, Washington, DC, USA; Rafael Alfonso, MD, MSc, University of Washington, Seattle, WA, USA

12:00-14:30 LUNCH, EXHIBITS & RESEARCH POSTER PRESENTATIONS VIEWING - SESSION II

12:30-13:30 EDUCATIONAL SYMPOSIUM

PRACTICAL APPLICATION OF REAL-WORLD EVIDENCE TO HEALTH TECHNOLOGY ASSESSMENT AND DECISION MAKING IN LATIN AMERICA: MOVING BEYOND THE THEORY TO PRACTICE

This session will review the importance of real-world evidence (RWE), given the growing trend of health technology assessment (HTA) in Latin America. A practical case of the use of RWE in a budget impact model for selected markets will be

SCHEDULE OF EVENTS

presented. How RWE represents a shift in the requirements of data used to inform different stakeholders and their potential application to Latin American Markets will also be discussed. *(Sponsored by IMS Health)*

13:30-14:30 RESEARCH POSTER AUTHOR DISCUSSION HOUR - SESSION II

14:30-15:30 WORKSHOPS - SESSION II

W6: ADVANCES IN META ANALYSIS: INCORPORATING MULTIPLE TREATMENTS, MULTIPLE ENDPOINTS, AND MULTIPLE STUDY DESIGNS *(Presented in English)*
Discussion Leaders: **Maria-Cecilia Vieira, MSc**, MAPI Group, Boston, MA, USA; **Issa Dahabreh, MD**, Brown University, Providence, RI, USA; **Shannon Cope, MSc**, MAPI Group, Boston, MA, USA; **Jeroen P. Jansen, PhD**, MAPI Group/Tufts University School of Medicine, Boston, MA, USA

W7: ISPOR-SMDM GOOD RESEARCH PRACTICES IN MODELING *(Presented in English)*

Discussion Leaders: **J. Jaime Caro, MDCM, FRCPC, FACP**, McGill University, Montreal, QC, Canada; **Andrew Briggs, DPhil, MSc**, University of Glasgow, Glasgow, UK; **Karen Kuntz, ScD**, Minneapolis, MN, USA; **Uwe Siebert, MD, MPH, MSc, ScD, UMIT / Oncotryol / Harvard University, Hall i.T., Innsbruck, Austria**

W8: USING EVIDENCE ELICITED FROM EXPERTS IN DECISION MAKING *(Presented in Spanish)*

Discussion Leaders: **Sebastian Garcia Marti, MD**, Institute for Clinical Effectiveness and Health Policy (IECS), Buenos Aires, Argentina; **Pedro Saramago, PhD**, University of York, Heslington, York, UK; **Marta O Soares, MSc**, University of York, Heslington, York, UK; **Manuel Antonio Espinoza, MD, PhD**, Pontificia Universidad Católica de Chile, Santiago, Chile

W9: HOW AND WHY MARKETS IN LATIN AMERICA NEED TO HAVE THEIR OWN COST-EFFECTIVENESS THRESHOLDS *(Presented in Spanish)*

Discussion Leaders: **Otávio Augusto Camara Clark, MD, PhD**, Evidencias, Campinas, Brazil; **Pedro Rizo Ríos, MD**, Consejo de Salubridad General, Mexico D.F., Mexico; **Rosa María Galindo-Suárez, MSc**, Pfizer S.A. de C.V., Mexico D.F., Mexico; **Lautaro Renati, BL, MA**, Instituto Nacional de Servicios Sociales para Jubilados y Pensionados - Argentina, Buenos Aires, Argentina

W10: SUCCESSFUL REAL WORLD DATA GENERATION AND USE IN LATIN AMERICA: EXPLORING THE POLICY PRINCIPLES, OPERATIONAL FRAMEWORK, AND ANALYTIC CONSIDERATIONS *(Presented in Spanish)*

Discussion Leaders: **Fernán Gonzalez Bernaldo de Quiroz, MD, MSc, FACMI**, Italian Hospital of Buenos Aires, Buenos Aires, Argentina; **Daniel Ferrante, MD, MSc**, Argentina Ministry of Health, Buenos Aires, Argentina; **Gerardo Machnicki, MSc, PhD**, Novartis Latin America & Canada, Buenos Aires, Argentina

15:30-15:45 BREAK, EXHIBITS, & RESEARCH POSTER PRESENTATIONS VIEWING - SESSION II

15:45-16:45 WORKSHOPS - SESSION III

W11: METANÁLISIS DE COMPARACIONES INDIRECTAS: Y SI NO HAY COMPARACIONES CABEZA A CABEZA? *(Presented in Spanish)*

Discussion Leaders: **Sebastian Garcia Marti, MD**, Institute for Clinical Effectiveness and Health Policy (IECS), Buenos Aires, Argentina; **Agustín Ciapponi, MD, MSc**, Institute for Clinical Effectiveness and Health Policy (IECS), Buenos Aires, Argentina; **Demian Glujovsky, MD MSc**, CEGYR, Buenos Aires, Argentina

W12: FROM HEAD-TO-HEAD COMPARISONS TO NETWORK META-ANALYSIS: CROSSING THE BRIDGE BETWEEN CLINICAL AND ECONOMIC OUTCOMES RESEARCH IN LATIN AMERICA *(Presented in English)*

Discussion Leaders: **Ximena Burbano-Levy, MD**, Zilonis Health, Inc., Boca Raton, FL, USA; **Marcelo Fonseca, MSc, MD**, Federal University of São Paulo and Axia.Bio Consulting, São Paulo, Brazil; **Gabriela Tannus, MSc**, Axia.Bio Consulting, São Paulo, Brazil; **David Thompson, PhD**, Quintiles, Cambridge, MA, USA

W13: TRANSFERABILITY OF COST-EFFECTIVENESS ANALYSIS: REQUIREMENTS TO IMPROVE DECISION MAKING IN LATIN AMERICA *(Presented in English)*

Discussion Leaders: **Manuel Antonio Espinoza, MD, MSc, PhD**, Pontificia Universidad Católica de Chile, Santiago, Chile; **Mark J. Sculpher, MSc, PhD**, University of York, Heslington, York, UK; **Federico Augustovski, MD, MSc, PhD**, Institute for Clinical Effectiveness and Health Policy (IECS) and University of Buenos Aires, Buenos Aires, Argentina; **Andrew Briggs, DPhil, MSc**, University of Glasgow, Glasgow, UK

W14: THE ROLE OF HTA IN DETERMINING ORPHAN AND SPECIALTY DRUG COVERAGE IN LATIN AMERICA *(Presented in English)*

Discussion Leaders: **Mónica Martin de Bustamante, AB**, CBPartners, Basel, Switzerland; **Rachel Beckerman, PhD**, CBPartners, New York, NY, USA; **Cyrus A. Chowdhury, MS**, CBPartners, New York City, NY, USA; **Corinna Sorenson, MPH, MHS**, London School of Economics and European Health Technology Institute for Socio-Economic Research, London, UK

W15: CHALLENGES OF MEDICAL DEVICES IN ECONOMIC ASSESSMENTS: A PERSPECTIVE OF LATIN AMERICA *(Presented in Spanish)*

Discussion Leaders: **Diana Téllez, MD, MPH**, Abbott Diagnostics, Bogota, Colombia; **Pablo Anaya, MPH**, Novartis Oncology, Mexico City, Mexico; **Hermilo Cabra**, Ethicon Endo-Surgery, Inc, Cincinnati, OH, USA

17:00-17:30 ISPOR RESEARCH PRESENTATIONS AWARDS, CLOSING REMARKS & RECEPTION

17:45-18:45 EDUCATIONAL SYMPOSIUM

CONFERENCE SPONSORSHIP & PROMOTIONAL OPPORTUNITIES

CORPORATE SPONSORS

ISPOR provides opportunities for organizations to financially support the ISPOR 4th Latin America Conference through educational grants called Corporate Sponsorships. Corporate sponsors receive complimentary conference registration(s) in addition to the benefits listed below. For further information, please email: laconsortium@ispor.org.

Benefits to All Sponsors:

- Recognition at the Plenary Sessions
- Recognition in the Program & Schedule of Events and on the ISPOR website
- Conference signage

EVENT SPONSORS

Increase your visibility! Give your company increased prominence.

For information, please email: eventsponsor@ispor.org.

Benefits to Event Sponsors:

- Listing and ¼ page advertisement in the Program & Schedule of Events
- Listing and ¼ page advertisement on the ISPOR website

ADVERTISE!

Advertise in the Program & Schedule of Events!

Advertising Deadline: 15 July 2013

EXHIBIT

Register now for exhibit space!

Present your products and services to key outcomes researchers and health care decision makers in pharmaceutical, medical device and diagnostics, biotechnology industries, clinical practice, government agencies, academia, and health care organizations.

Benefits to Exhibitors:

- Listing and ¼ page advertisement in the Program & Schedule of Events
- Listing and ¼ page advertisement on the ISPOR website
- Complimentary conference registration
- Pre-registrant mailing labels

ISPOR 4TH LATIN AMERICA CONFERENCE

12-14 SEPTEMBER 2013 • BUENOS AIRES, ARGENTINA

CONFERENCE REGISTRATION

FIRST NAME	LAST NAME	DEGREES	MEMBER ID#
POSITION		ORGANIZATION	
MAILING ADDRESS			
CITY	STATE	ZIP	COUNTRY
TELEPHONE	FAX	EMAIL	

PRE-CONFERENCE SHORT COURSES THROUGH 23 JULY 2013	AFTER 23 JULY 2013	FEE
---	--------------------	-----

12 SEPTEMBER 2013 (Short Course registration is optional and is in addition to Conference Registration fee.)

ALL DAY SHORT COURSES (9:00-18:00)	Regular: \$200 (ARS 1040) Student: \$100 (ARS 520)	Regular: \$400 (ARS 2080) Student: \$200 (ARS 1040)
---	--	---

- | | |
|---|----------|
| <input type="checkbox"/> INTRODUCTION TO HEALTH ECONOMICS FOR DECISION MAKERS | \$ _____ |
| <input type="checkbox"/> INTRODUCTION TO MODELING | \$ _____ |

MORNING SHORT COURSES (9:00-13:00)	Regular: \$100 (ARS 520) Student: \$50 (ARS 237)	Regular: \$200 (ARS 1040) Student: \$100 (ARS 520)
---	--	--

- | | |
|--|----------|
| <input type="checkbox"/> EXTRACTING COST DATA FOR ECONOMIC ANALYSIS IN LATIN AMERICA | \$ _____ |
| <input type="checkbox"/> HEALTH-RELATED QUALITY OF LIFE / UTILITY MEASURES | \$ _____ |

AFTERNOON SHORT COURSES (14:00-18:00)	Regular: \$100 (ARS 520) Student: \$50 (ARS 237)	Regular: \$200 (ARS 1040) Student: \$100 (ARS 520)
--	--	--

- | | |
|---|----------|
| <input type="checkbox"/> APPLIED MODELING | \$ _____ |
| <input type="checkbox"/> BUDGET IMPACT ANALYSIS | \$ _____ |

CONFERENCE REGISTRATION	THROUGH 23 JULY 2013	AFTER 23 JULY 2013	FEE
-------------------------	----------------------	--------------------	-----

13-14 SEPTEMBER 2013

STANDARD	US \$400 (ARS 2080)	US \$500 (ARS 2600)	\$ _____
CLINICAL PRACTITIONERS (Clinical Practice, Hospital)	US \$400 (ARS 2080)	US \$500 (ARS 2600)	\$ _____
FULL-TIME GOVERNMENT AND ACADEMIA	US \$200 (ARS 1040)	US \$300 (ARS 1560)	\$ _____
FULL-TIME STUDENTS (must provide current enrollment docs)	US \$80 (ARS 415)	US \$100 (ARS 520)	\$ _____

ISPOR MEMBERSHIP (OPTIONAL)	FEE
-----------------------------	-----

MEMBER	\$ _____
---------------	----------

USD \$275 – includes 1-year subscription to Value in Health (online & hard copy, including access to all past issues) and a 1-year-bi-monthly subscriptions to *ISPOR CONNECTIONS* (online and print).

USD \$140 – includes 1-year online subscription to Value in Health (online access to all past issues) and a 1-year-bi-monthly subscriptions to *ISPOR CONNECTIONS* (online and print).

STUDENT MEMBER	\$ _____
-----------------------	----------

USD \$120 – includes 1-year subscription to Value in Health (online & hard copy, including access to all past issues) and a 1-year-bi-monthly subscriptions to *ISPOR CONNECTIONS* (online and print).

USD \$35 – includes 1-year online subscription to Value in Health (online access to all past issues) and a 1-year-bi-monthly subscriptions to *ISPOR CONNECTIONS* (online and print).

AMOUNT DUE	Short Course Fee + Conference Registration Fee = TOTAL FEE \$ _____
-------------------	--

PAYMENT INFORMATION

Note: Exchange rate as of May 2013. The ARS rates should be used as a reference only. All credit card payments to ISPOR are charged in USD\$ at the exchange rate prevailing at the time of the transaction. Due to this exchange, credit card statements may vary slightly.

Please enclose a check payable in US dollars to: International Society for Pharmacoeconomics and Outcomes Research or ISPOR and send to the ISPOR address below.

Charge to: VISA MasterCard American Express Account Number: _____ Expiration Date: _____

Name: _____ Authorized Signature: _____

MAIL DETAILS: If not paying by credit card online, send registration form and payment to: International Society for Pharmacoeconomics and Outcomes Research, 505 Lawrence Square Blvd South, Lawrenceville, NJ 08648 USA • Tel: 609-586-4981 • Fax: 609-586-4982 • E-Mail: info@ispor.org • Internet: www.ispor.org

PAYMENT DETAILS: Payment can be made by check, bank transfer (\$40USD additional charge) or credit card (Visa, MasterCard, American Express). All credit card payments will be charged in USD. Phone charges will NOT be accepted. If payment is being made by your company, please make sure your name is indicated on the check stub or correspondence for bank transfer.

CANCELLATION DETAILS: Cancellation fee before 23 July 2013 is US \$100. **No refunds given after 23 July 2013.**

For more information: www.ispor.org

Register Online @ www.ispor.org